Scalp
Tildrakizumab shows long-term scalp psoriasis improvement
Scalp psoriasis improvement was maintained with long-term tildrakizumab treatment in what researchers said is the first “dedicated trial” to demonstrate sustainable efficacy of an anti-interleukin-23 inhibitor for the condition.
‘A valuable treatment’: Roflumilast foam 0.3% shows positive PROs in scalp, body psoriasis
Roflumilast foam 0.3% improved patient-reported outcomes in scalp and body psoriasis, according to a poster presentation at the Fall Clinical Dermatology Conference.
Bimekizumab maintains scalp, palmoplantar psoriasis clearance through 4 years
Patients with scalp and palmoplantar psoriasis treated with bimekizumab had a high rate of clearance maintained through 4 years of treatment, according to a poster presented at the European Academy of Dermatology and Venereology Congress.
Phase 3, real-world data show deucravacitinib efficacious for scalp, overall psoriasis
Deucravacitinib proved to be efficacious in the treatment of moderate to severe scalp psoriasis and less extensive overall psoriasis, according to two presentations at the European Academy of Dermatology and Venerology Congress.
FDA accepts supplemental application for Zoryve foam for scalp, body psoriasis
The FDA has accepted Arcutis Biotherapeutics’ supplemental new drug application for Zoryve foam 0.3% for the treatment of scalp and body psoriasis in adults and adolescents aged 12 years and older, the company announced in a press release.
Arcutis submits sNDA for Zoryve foam 0.3% for scalp, body psoriasis
Arcutis has submitted a supplemental new drug application for Zoryve foam 0.3% for the treatment of scalp and body psoriasis in adults and adolescents aged 12 years and older, according to a company press release.
FDA expands Klisyri approval for actinic keratosis treatment on larger face, scalp areas
The FDA has approved the expanded use area of Klisyri to up to 100 cm2 on the face and scalp for the treatment of actinic keratosis, Almirall announced in a press release.
Tildrakizumab proves effective as treatment for scalp psoriasis
Tildrakizumab was efficacious in the treatment of patients with moderate to severe plaque psoriasis affecting the scalp and presented no new safety signals, according to a study.
Phase 3 data show Tremfya improves scalp psoriasis in patients with skin of color
Patients with skin of color that suffer from scalp psoriasis saw significant improvement in their disease severity, scalp itch and quality of life outcomes when treated with Tremfya, according to newly released phase 3 results.
Patient-reported outcomes favor roflumilast vs. vehicle in scalp, body psoriasis treatment
New results, including patient-reported outcome data, from the phase 3 ARRECTOR trial show roflumilast foam 0.3% continues to improve scalp and body psoriasis in adults, Arcutis announced in a press release.